{"title":"丙戊酸钠安全处方指南","authors":"Aisling Molloy","doi":"10.1002/psb.2115","DOIUrl":null,"url":null,"abstract":"New regulatory changes were introduced in January further restricting the prescription of valproate medicines in patients under 55 years of age due to the significant reproductive risks. This article discusses these changes as well as the other issues to consider to ensure valproate prescribing is as safe as possible, including monitoring for adverse effects and avoiding interactions.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A guide to prescribing valproate medicines safely\",\"authors\":\"Aisling Molloy\",\"doi\":\"10.1002/psb.2115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"New regulatory changes were introduced in January further restricting the prescription of valproate medicines in patients under 55 years of age due to the significant reproductive risks. This article discusses these changes as well as the other issues to consider to ensure valproate prescribing is as safe as possible, including monitoring for adverse effects and avoiding interactions.\",\"PeriodicalId\":20432,\"journal\":{\"name\":\"Prescriber\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/psb.2115\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
New regulatory changes were introduced in January further restricting the prescription of valproate medicines in patients under 55 years of age due to the significant reproductive risks. This article discusses these changes as well as the other issues to consider to ensure valproate prescribing is as safe as possible, including monitoring for adverse effects and avoiding interactions.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
